中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 41 Issue 8
Aug.  2025
Turn off MathJax
Article Contents

Effect of triglyceride-glucose index combined with C-reactive protein on new-onset nonalcoholic fatty liver disease

DOI: 10.12449/JCH250812
Research funding:

2024 Medical Science Research Project of Hebei Provincial Health Commission (20242051)

More Information
  • Corresponding author: MA Xiangming, brighter_ma@163.com (ORCID: 0009-0005-4182-7244)
  • Received Date: 2024-12-20
  • Accepted Date: 2025-02-11
  • Published Date: 2025-08-25
  •   Objective  To investigate whether there is a synergistic pathogenic effect between triglyceride glucose index (TyG) and C-reactive protein (CRP) on new-onset nonalcoholic fatty liver disease (NAFLD) by observing the influence of combinations of TyG and CRP at different levels, and to provide a basis for identifying the high-risk population of NAFLD.  Methods  A total of 31 935 employees in Kailuan Group who participated in physical examination in 2006 — 2007 were enrolled as the observation cohort, and they had no history of drinking, fatty liver disease, cardiovascular disease, or malignant tumor and did not take antidiabetic or lipid-lowering drugs. According to the median of TyG and CRP at baseline, the subjects were divided into TyG<8.42 and CRP<0.60 mg/L group, TyG<8.42 and CRP≥0.60 mg/L group, TyG≥8.42 and CRP<0.60 mg/L group, and TyG≥8.42 and CRP≥0.60 mg/L group. A one-way analysis of variance was used for comparison of normally distributed continuous data between multiple groups, and an analysis of variance was used for comparison of continuous data with skewed distribution between groups after logarithmic transformation; the chi-square test was used for comparison of categorical data between groups. The Kaplan-Meier method was used to calculate the cumulative incidence rate of NAFLD in different combinations of CRP and TyG levels, and the multivariate Cox regression model was used to investigate the influence of different combinations of TyG and CRP on the incidence rate of NAFLD.  Results  After a mean follow-up time of 7.59 years, a total of 16 592 employees developed NAFLD. The cumulative incidence rate of NAFLD in the TyG<8.42 and CRP<0.60 mg/L group, TyG<8.42 and CRP≥0.60 mg/L group, TyG≥8.42 and CRP<0.60 mg/L group, and TyG≥8.42 and CRP≥0.60 mg/L group were 59.5%, 67.1%, 73.8%, and 80.8%, respectively (P<0.001). After adjustment for confounding factors, compared with the TyG<8.42 and CRP<0.60 mg/L group, the TyG≥8.42 and CRP≥0.60 mg/L group had the highest risk of developing NAFLD (hazard ratio [HR]=1.54, 95% confidence interval [CI]: 1.47 — 1.61), followed by the TyG≥8.42 and CRP<0.60 mg/L group (HR=1.43, 95%CI: 1.36 — 1.49) and the TyG<8.42 and CRP≥0.60 mg/L group (HR=1.17, 95%CI: 1.12 — 1.22).  Conclusion  With elevated TyG and CRP levels, the cumulative incidence of NAFLD increased, and rising levels of these markers significantly augmented the risk of NAFLD development.

     

  • loading
  • [1]
    YOUNOSSI ZM, KOENIG AB, ABDELATIF D, et al. Global epidemiology of nonalcoholic fatty liver disease: Meta-analytic assessment of prevalence, incidence, and outcomes[J]. Hepatology, 2016, 64( 1): 73- 84. DOI: 10.1002/hep.28431.
    [2]
    BYRNE CD, TARGHER G. Non-alcoholic fatty liver disease-related risk of cardiovascular disease and other cardiac complications[J]. Diabetes Obes Metab, 2022, 24( Suppl 2): 28- 43. DOI: 10.1111/dom.14484.
    [3]
    MUSSO G, GAMBINO R, TABIBIAN JH, et al. Association of non-alcoholic fatty liver disease with chronic kidney disease: A systematic review and meta-analysis[J]. PLoS Med, 2014, 11( 7): e1001680. DOI: 10.1371/journal.pmed.1001680.
    [4]
    MANTOVANI A, PETRACCA G, BEATRICE G, et al. Non-alcoholic fatty liver disease and increased risk of incident extrahepatic cancers: A meta-analysis of observational cohort studies[J]. Gut, 2022, 71( 4): 778- 788. DOI: 10.1136/gutjnl-2021-324191.
    [5]
    LI F, LI MW, WANG YS. Therapeutic paradigms and potential therapies for nonalcoholic steatohepatitis[J]. J Clin Hepatol, 2024, 40( 10): 2082- 2086. DOI: 10.12449/JCH241025.

    李凤, 李茂微, 王雨杉. 非酒精性脂肪肝病的治疗模式和潜在疗法[J]. 临床肝胆病杂志, 2024, 40( 10): 2082- 2086. DOI: 10.12449/JCH241025.
    [6]
    LI L, LIU DW, YAN HY, et al. Obesity is an independent risk factor for non-alcoholic fatty liver disease: Evidence from a meta-analysis of 21 cohort studies[J]. Obes Rev, 2016, 17( 6): 510- 519. DOI: 10.1111/obr.12407.
    [7]
    VACHLIOTIS I, GOULAS A, PAPAIOANNIDOU P, et al. Nonalcoholic fatty liver disease: Lifestyle and quality of life[J]. Hormones(Athens), 2022, 21( 1): 41- 49. DOI: 10.1007/s42000-021-00339-6.
    [8]
    MARJOT T, MOOLLA A, COBBOLD JF, et al. Nonalcoholic fatty liver disease in adults: Current concepts in etiology, outcomes, and management[J]. Endocr Rev, 2020, 41( 1): bnz009. DOI: 10.1210/endrev/bnz009.
    [9]
    ZHU F, WANG LM, JI CP, et al. Relationship between the C-reactive protein and nonalcoholic fatty liver disease prevalence[J]. Clin Med China, 2015, 31( 9): 812- 816. DOI: 10.3760/cma.j.issn.1008- 6315.2015.09.013.

    朱峰, 王来明, 季春鹏, 等. 血清C反应蛋白与非酒精性脂肪性肝病的相关性研究[J]. 中国综合临床, 2015, 31( 9): 812- 816. DOI: 10.3760/cma.j.issn.1008- 6315.2015.09.013.
    [10]
    ZHU F, WANG LM, JI CP, et al. Predictive value of C-reactive protein in emerging non-alcoholic fatty liver disease[J]. Chin J Hepatol, 2016, 24( 8): 575- 579. DOI: 10.3760/cma.j.issn.1007-3418. 2016.08.004.

    朱峰, 王来明, 季春鹏, 等. C-反应蛋白对新发非酒精性脂肪肝的预测价值[J]. 中华肝脏病杂志, 2016, 24( 8): 575- 579. DOI: 10.3760/cma.j.issn.1007-3418.2016.08.004.
    [11]
    CHEN CX, DU J, SONG J, et al. Study on correlation between serum hypersensitive C-reactive protein and nonalcoholic fatty liver disease in the elderly[J]. Chin J Gen Prac, 2023, 21( 9): 1491- 1494. DOI: 10.16766/j.cnki.issn.1674-4152.003153.

    陈长喜, 杜娟, 宋健, 等. 血清超敏C反应蛋白与老年人非酒精性脂肪肝的相关性[J]. 中华全科医学, 2023, 21( 9): 1491- 1494. DOI: 10.16766/j.cnki.issn.1674-4152.003153.
    [12]
    LING Q, CHEN JW, LIU X, et al. The triglyceride and glucose index and risk of nonalcoholic fatty liver disease: A dose-response meta-analysis[J]. Front Endocrinol(Lausanne), 2023, 13: 1043169. DOI: 10.3389/fendo.2022.1043169.
    [13]
    National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association, Fatty Liver Expert Committee, Chinese Medical Doctor Association. Guidelines of prevention and treatment for nonalcoholic fatty liver disease: A 2018 update[J]. J Clin Hepatol, 2018, 34( 5): 947- 957. DOI: 10.3969/j.issn.1001-5256.2018.05.007.

    中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南(2018年更新版)[J]. 临床肝胆病杂志, 2018, 34( 5): 947- 957. DOI: 10.3969/j.issn.1001-5256.2018.05.007.
    [14]
    ZHENG RJ, DU ZN, WANG MM, et al. A longitudinal epidemiological study on the triglyceride and glucose index and the incident nonalcoholic fatty liver disease[J]. Lipids Health Dis, 2018, 17( 1): 262. DOI: 10.1186/s12944-018-0913-3.
    [15]
    KIM KS, HONG SM, AHN HY, et al. Triglyceride and glucose index is a simple and easy-to-calculate marker associated with nonalcoholic fatty liver disease[J]. Obesity(Silver Spring), 2022, 30( 6): 1279- 1288. DOI: 10.1002/oby.23438.
    [16]
    LEE J, YOON K, RYU S, et al. High-normal levels of hs-CRP predict the development of non-alcoholic fatty liver in healthy men[J]. PLoS One, 2017, 12( 2): e0172666. DOI: 10.1371/journal.pone.0172666.
    [17]
    ZHANG YX, WANG Y, YOU CL, et al. Analysis of related factors of abnormal liver function in patients with nonalcoholic fatty liver disease[J]. Clin J Med Offic, 2025, 53( 5): 522- 524,528. DOI: 10.16680/j.1671-3826.2025.05.21.

    张月霞, 王宇, 尤丛蕾, 等. 非酒精性脂肪肝患者肝功能异常相关因素分析[J]. 临床军医杂志, 2025, 53( 5): 522- 524, 528. DOI: 10.16680/j.1671-3826.2025.05.21.
    [18]
    LEE JW, CHO YK, RYAN M, et al. Serum uric Acid as a predictor for the development of nonalcoholic fatty liver disease in apparently healthy subjects: A 5-year retrospective cohort study[J]. Gut Liver, 2010, 4( 3): 378- 383. DOI: 10.5009/gnl.2010.4.3.378.
    [19]
    KIDA Y, SATO T. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease[J]. Ann Intern Med, 2006, 144( 5): 379- 380; author reply 380. DOI: 10.7326/0003-4819-144-5-200603070-00022.
    [20]
    MIN YY, ZHANG P, TIAN PR, et al. The mechanism of bariatric surgery in the treatment of non-alcoholic fatty liver disease[J]. Chin J Dig Surg, 2024, 23( 9): 1231- 1236. DOI: 10.3760/cma.j.cn115610-20240614-00296.

    闵逸洋, 张鹏, 田沛荣, 等. 减重手术治疗非酒精性脂肪性肝病的作用机制[J]. 中华消化外科杂志, 2024, 23( 9): 1231- 1236. DOI: 10.3760/cma.j.cn115610-20240614-00296.
    [21]
    GRANDER C, GRABHERR F, TILG H. Non-alcoholic fatty liver disease: Pathophysiological concepts and treatment options[J]. Cardiovasc Res, 2023, 119( 9): 1787- 1798. DOI: 10.1093/cvr/cvad095.
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(4)

    Article Metrics

    Article views (377) PDF downloads(36) Cited by()
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return